Levodopa and L-tryptophan therapy in Parkinsonism.
D000368:Aged; D003863:Depression; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005684:Gait; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009788:Occupational Therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010555:Personality Inventory; D026741:Physical Therapy Modalities; D011187:Posture; D011569:Psychiatric Status Rating Scales; D013035:Spasm / Q000188:drug therapy; D013070:Speech Therapy; D014202:Tremor / Q000188:drug therapy; D014364:Tryptophan / Q000009:adverse effects / Q000627:therapeutic use*
D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D014364:Tryptophan; D006719:Homovanillic Acid